The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people ...

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

Kennedy’s FDA approved the use of the Novavax Covid-19 vaccine, but with strict conditions. It will only be made available to older people and those over the age of 12 with at least one medical ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

The gravity of these decisions calls for a degree of humility on the part of an FDA leader. And that’s the rub with Vinay ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.